Laboratorio de Biomedicina y Biología Molecular, Unidad Académica de Ingeniería en Biotecnología, Universidad Politécnica de Sinaloa, Culiacán, México.
Posgrado en Ciencias Biomédicas, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa, Culiacán, México.
J Cancer Res Ther. 2020 Oct-Dec;16(6):1223-1228. doi: 10.4103/jcrt.JCRT_1111_19.
MicroRNAs (miRNAs) are involved in the regulation of genes with important roles in cancer. Therefore, they represent interesting targets as biomarkers for early detection, follow-up, and prognosis of the disease.
In early stages of breast cancer, differences in the expression of miR-148b-3p, miR-145-5p and miR-133a-3p have been reported.
To compare the expression of miR-148b-3p, miR-145-5p and miR-133a-3p in serum samples from female patients with and without breast cancer.
Case control study.
We quantified the expression by real-time polymerase chain reaction of miR-148b-3p, miR-145-5p, and miR-133a-3p in serum samples from 27 breast cancer (BC) and 17 benign breast tumor patients.
Comparison between groups with categorical variables was made using the Pearson's Chi-square test. Comparative analysis for continuous variables between two groups was performed using the Student's t-test. One-way analysis of variance (ANOVA) was used for multigroup comparison, followed by Tukey HSD analysis.
The use of contraceptives and a high number of births were identified as risk factors for BC. We observed that miR-145-5p expresses in low levels in BC and positively diagnosed Her2 patients. In addition, BC patients with either ductal carcinoma or positive molecular diagnosis for estrogen receptor, progesterone receptor, luminal A, or Her2 negative, presented a decreased expression of miR-133a-3p.
We observed an existing association between the molecular characteristics of BC and levels of circulating miR-133a-3p and miR-145-5p, proving the potential role of miRNAs as biomarkers for BC.
微小 RNA（miRNA）参与基因调控，在癌症中具有重要作用。因此，它们作为早期检测、随访和疾病预后的生物标志物具有很大的研究价值。
在乳腺癌的早期阶段，已经报道了 miR-148b-3p、miR-145-5p 和 miR-133a-3p 的表达差异。
比较有和无乳腺癌女性患者血清样本中 miR-148b-3p、miR-145-5p 和 miR-133a-3p 的表达。
病例对照研究。
我们通过实时聚合酶链反应定量检测了 27 例乳腺癌（BC）和 17 例良性乳腺肿瘤患者血清样本中 miR-148b-3p、miR-145-5p 和 miR-133a-3p 的表达。
采用 Pearson 卡方检验比较组间分类变量，采用 Student's t 检验比较两组间连续变量。采用单因素方差分析（ANOVA）比较多组间差异，然后采用 Tukey HSD 分析进行多重比较。
使用避孕药和生育次数多被认为是乳腺癌的危险因素。我们发现 miR-145-5p 在乳腺癌中表达水平较低，并能对 Her2 阳性患者进行准确诊断。此外，导管癌或雌激素受体、孕激素受体、腔 A 或 Her2 阴性等分子诊断阳性的乳腺癌患者，miR-133a-3p 表达水平降低。
我们观察到乳腺癌的分子特征与循环 miR-133a-3p 和 miR-145-5p 的水平之间存在关联，证明了 miRNA 作为乳腺癌生物标志物的潜力。
